KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Gross Profit (2016 - 2025)

Historic Gross Profit for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $83.3 million.

  • Neogenomics' Gross Profit rose 787.76% to $83.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $314.3 million, marking a year-over-year increase of 833.95%. This contributed to the annual value of $314.3 million for FY2025, which is 833.95% up from last year.
  • Latest data reveals that Neogenomics reported Gross Profit of $83.3 million as of Q4 2025, which was up 787.76% from $80.4 million recorded in Q3 2025.
  • Neogenomics' Gross Profit's 5-year high stood at $83.3 million during Q4 2025, with a 5-year trough of $38.2 million in Q1 2022.
  • For the 5-year period, Neogenomics' Gross Profit averaged around $61.2 million, with its median value being $61.1 million (2023).
  • Examining YoY changes over the last 5 years, Neogenomics' Gross Profit showed a top increase of 8920.95% in 2021 and a maximum decrease of 2122.78% in 2021.
  • Neogenomics' Gross Profit (Quarter) stood at $45.3 million in 2021, then rose by 25.56% to $56.8 million in 2022, then grew by 18.94% to $67.6 million in 2023, then grew by 14.31% to $77.3 million in 2024, then grew by 7.88% to $83.3 million in 2025.
  • Its last three reported values are $83.3 million in Q4 2025, $80.4 million for Q3 2025, and $77.3 million during Q2 2025.